Cargando…
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
Although survival of multiple myeloma patients has at least doubled during recent years, most patients eventually relapse, and treatment at this stage may be particularly complex. At the time of relapse, the use of alternative drugs to those given upfront is current practice. However, many new optio...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756574/ https://www.ncbi.nlm.nih.gov/pubmed/29188449 http://dx.doi.org/10.1007/s40265-017-0841-y |
_version_ | 1783290745712541696 |
---|---|
author | Nijhof, Inger S. van de Donk, Niels W. C. J. Zweegman, Sonja Lokhorst, Henk M. |
author_facet | Nijhof, Inger S. van de Donk, Niels W. C. J. Zweegman, Sonja Lokhorst, Henk M. |
author_sort | Nijhof, Inger S. |
collection | PubMed |
description | Although survival of multiple myeloma patients has at least doubled during recent years, most patients eventually relapse, and treatment at this stage may be particularly complex. At the time of relapse, the use of alternative drugs to those given upfront is current practice. However, many new options are currently available for the treatment of relapsed multiple myeloma, including recently approved drugs, such as the second- and third-generation proteasome inhibitors carfilzomib and ixazomib, the immunomodulatory agent pomalidomide, the monoclonal antibodies daratumumab and elotuzumab and the histone deacetylase inhibitor panobinostat, but also new targeted agents are under active investigation (e.g. signal transduction modulators, kinesin spindle protein inhibitors, and inhibitors of NF-kB, MAPK, AKT). We here describe a new paradigm for the treatment of relapsed multiple myeloma. The final goal should be finding a balance among efficacy, toxicity, and cost and, at the end of the road, achieving long-lasting control of the disease and eventually even cure in a subset of patients. |
format | Online Article Text |
id | pubmed-5756574 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-57565742018-01-22 Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update Nijhof, Inger S. van de Donk, Niels W. C. J. Zweegman, Sonja Lokhorst, Henk M. Drugs Review Article Although survival of multiple myeloma patients has at least doubled during recent years, most patients eventually relapse, and treatment at this stage may be particularly complex. At the time of relapse, the use of alternative drugs to those given upfront is current practice. However, many new options are currently available for the treatment of relapsed multiple myeloma, including recently approved drugs, such as the second- and third-generation proteasome inhibitors carfilzomib and ixazomib, the immunomodulatory agent pomalidomide, the monoclonal antibodies daratumumab and elotuzumab and the histone deacetylase inhibitor panobinostat, but also new targeted agents are under active investigation (e.g. signal transduction modulators, kinesin spindle protein inhibitors, and inhibitors of NF-kB, MAPK, AKT). We here describe a new paradigm for the treatment of relapsed multiple myeloma. The final goal should be finding a balance among efficacy, toxicity, and cost and, at the end of the road, achieving long-lasting control of the disease and eventually even cure in a subset of patients. Springer International Publishing 2017-11-29 2018 /pmc/articles/PMC5756574/ /pubmed/29188449 http://dx.doi.org/10.1007/s40265-017-0841-y Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Article Nijhof, Inger S. van de Donk, Niels W. C. J. Zweegman, Sonja Lokhorst, Henk M. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update |
title | Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update |
title_full | Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update |
title_fullStr | Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update |
title_full_unstemmed | Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update |
title_short | Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update |
title_sort | current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756574/ https://www.ncbi.nlm.nih.gov/pubmed/29188449 http://dx.doi.org/10.1007/s40265-017-0841-y |
work_keys_str_mv | AT nijhofingers currentandnewtherapeuticstrategiesforrelapsedandrefractorymultiplemyelomaanupdate AT vandedonknielswcj currentandnewtherapeuticstrategiesforrelapsedandrefractorymultiplemyelomaanupdate AT zweegmansonja currentandnewtherapeuticstrategiesforrelapsedandrefractorymultiplemyelomaanupdate AT lokhorsthenkm currentandnewtherapeuticstrategiesforrelapsedandrefractorymultiplemyelomaanupdate |